Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Bemarituzumab · AMG-552, FPA-144

Monoclonal antibody · Antagonist of FGFR2b (FGFR2) · developed by AMGEN

Phase 3 Most advanced trial (none active)
AMGN Developer
1 Registered trials

What is Bemarituzumab?

Bemarituzumab is a glycoengineered humanized monoclonal antibody that binds to FGFR2b on tumor cells, blocking ligand activation and inducing antibody-dependent cell-mediated cytotoxicity. It is studied in gastric and gastroesophageal junction adenocarcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
AMG-552, FPA-144
Drug type
Monoclonal antibody
Targets
FGFR2b (FGFR2)
Mechanism
Antagonist of FGFR2b (FGFR2)
Pathways
FGFR2b-mediated signal transduction, cell proliferation, apoptosis
Therapy area
Oncology
Developer
AMGEN (AMGN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
RJW23BQ0KW

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05111626 Phase 3 Gastric Cancer Terminated AMGN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Gastric CancerGastroesophageal Junction Adenocarcinoma

Other drugs acting on FGFR2

Nintedanib FDA approved CGT4859 Phase 1/2

More from AMGEN

Apremilast FDA approved Blinatumomab FDA approved Carfilzomib FDA approved Denosumab FDA approved Erenumab FDA approved Evolocumab FDA approved Pegloticase FDA approved Prednisone FDA approved Romiplostim FDA approved Romosozumab FDA approved Sotorasib FDA approved Tarlatamab FDA approved

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the AMGN page.

Follow AMGN, the company behind Bemarituzumab

See AMGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AMGN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.